AI Consensus Investment Thesis
UCB (UCB) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
Strong Buy & Hold
High conviction across horizons supports patient long-term ownership.
1-Year
STRONG BUY€288
+29.9%+30.6% incl. dividends5-Year
BUY€425
+91.5%+96.3% incl. dividendsLatest flagship insight
Unlevered Immunology Leader Set to Outperform Amid Global Stagflation and Rate Pressures
High consensus exists regarding the asset's transition into a self-funding immunology powerhouse, insulated from macroeconomic shocks by its unlevered balance sheet. While US pricing regulations and legacy patent cliffs present structural frictions, the rapid global scaling of its blockbuster immunology portfolio remains the primary driver of long-term value.
This is the latest published deep-analysis batch. Audit previous forecasts in full transparency
Warren Buffett (Value Purist), Superintelligence (Anthropologist), Ray Dalio (Strategist), Machiavelli (Insider), Elon Musk (Visionary), Michael Burry (Vulture), J.P. Morgan (Titan), Sherlock Holmes (Whistleblower). Some archetypes run in multiple modes, resulting in 12 advisors total.
Research support only. We don't give financial advice.
Gemini
Claude
ChatGPT
GrokExecutive Summary
Dotted terms open concise definitions. Browse technical terms
Interactive forecast chart
The asset is undergoing a structural transition from a legacy neurology-focused firm into a high-margin, self-funding immunology powerhouse. Backed by an exceptionally low debt-to-equity ratio of 0.21 and robust free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry generation, the company is highly insulated from the current restrictive monetary regimemonetary regimeThe prevailing framework of central-bank policy, interest rates, money creation, and exchange-rate management.View full glossary entry and European stagflationeuropean stagflationAn economic environment in Europe combining weak growth with persistent inflation.View full glossary entry. While legacy patent cliffs and US pricing regulations act as persistent frictions, the rapid global scaling of its blockbuster immunology portfolio and rare disease franchise will drive sustained intrinsic valueintrinsic valueThe estimated true worth of a business or asset based on fundamentals instead of short-term market mood.View full glossary entry compounding over the five-year horizon.
Key insights
- Best-in-class clinical efficacy of the core immunology asset drives rapid global market share capture and establishes a widening economic moateconomic moatCompetitive advantage protecting market share and profitability from rivals.View full glossary entry.
- Pristine balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry with minimal leverage completely insulates the capital structurecapital structureThe mix of debt and equity used to finance a business.View full glossary entry from refinancing risks and elevated borrowing costs.
- Low physical capital intensitycapital intensityA business condition where large upfront spending on assets and infrastructure is needed to operate and grow.View full glossary entry combined with high cash conversion yields an elite free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry profile that funds organic pipeline expansion.
- Strategic onshoring of manufacturing networks establishes a robust geopolitical moat against supply chainsupply chainThe network of suppliers, producers, logistics providers, distributors, and customers involved in creating and delivering a product or service.View full glossary entry disruptions and regulatory decoupling pressures.
- Near-term margin compressionmargin compressionThe narrowing of profit margins due to rising costs or declining pricing power.View full glossary entry from recent clinical-stage acquisitions represents a temporary capital allocationcapital allocationThe decision process for directing capital among operations, investment, acquisitions, debt repayment, dividends, and share repurchases.View full glossary entry drag rather than structural operational decay.
- Regulatory pricing pressures in the US market limit terminal pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry but fail to derail the volume-driven growth trajectory.
- Integration of advanced computational biology and AI-driven drug discovery platforms structurally accelerates pipeline velocity and reduces long-term R&D costs.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Forecasts—and what could close the gap?
Market Narrative
What does the market currently expect? The prevailing market consensus views the asset through a conventional, single-product lens, focusing heavily on the commercial launch of its flagship immunology drug to offset patent cliffs for legacy epilepsy treatments. Sell-side analysts and media outlets largely treat the company as a standard, defensive European pharmaceutical play. They anchor their valuations to near-term prescription volumes and competitive battles in the immunology market. Furthermore, the crowd remains skeptical of recent clinical-stage acquisitions, viewing them as expensive attempts to buy growth that drag on near-term margins, while overlooking the structural transformation of the company's underlying cash-flow generation capabilities.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The core information gap lies in the market's failure to recognize the asset's profound balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry resilience and structural cash-flow dynamics within a hostile macroeconomic environment. While the crowd values the company as a typical product-cycle biopharma vulnerable to multiple compressionmultiple compressionA decline in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry, it operates as an unlevered, self-funding compounding engine with a debt-to-equity ratio of just 0.21 and expanding free cash flow marginsfree cash flow marginsThe percentage of revenue converted into cash after accounting for capital expenditures and operating costs.View full glossary entry. Furthermore, the market systematically misprices the geopolitical premium of the company's localized European and US manufacturing networks. In a regime dominated by supply chainsupply chainThe network of suppliers, producers, logistics providers, distributors, and customers involved in creating and delivering a product or service.View full glossary entry decoupling and the BIOSECURE Actbiosecure actBiosecure Act refers to legislation aimed at limiting reliance on certain biotechnology suppliers or data-linked firms for national security reasons.View full glossary entry, this localized infrastructure transitions from an operational detail into a major competitive advantage, shielding the firm from disruptions that threaten China-dependent peers.
Repricing Catalyst
What could make the market recognize and close that gap? The convergence of the crowd narrative toward the consensus will be triggered by successive quarterly earnings reports demonstrating sustained free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry expansion and gross margingross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry resilience despite global stagflationglobal stagflationAn economic environment characterized by stagnant growth and high inflation, pressuring corporate margins and spending.View full glossary entry. This operational strength will be highlighted by the flagship immunology drug consistently beating market share estimates. Additionally, the successful integration of recent acquisitions and the validation of onshored manufacturing facilities will dismantle the margin-decay thesis. As trailing valuation multiples compress mechanically against soaring earnings, generalist macro allocators will be forced to rotate capital into the asset as a high-yield, zero-leverage safe haven.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Mixed
- Volatility
- Moderate
- Cycle position
- Growing Awareness
While there is strong agreement on the asset's growing awareness phase, minor disagreements persist regarding near-term sentiment. Some perspectives highlight cautious fear due to US regulatory pricing overhangs and patent cliffs, while others reflect greed driven by explosive top-line growth and commercial execution. Expected volatility is generally viewed as moderate, though some expect low, steady trading.
Macro Regime Fit
Does the current market environment support the thesis? The current macroeconomic backdrop of war-driven stagflationstagflationAn economic condition characterized by stagnant growth, high unemployment, and high inflation.View full glossary entry, persistent inflation, and restrictive monetary policy serves as a powerful relative tailwind. While high interest rates and tightening credit conditions severely penalize leveraged, capital-intensive equities, the asset's minimal debt and self-funding cash generation render it virtually immune to refinancing risks. Furthermore, demand for its severe-disease therapeutics is highly inelastic, protecting operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry from cyclical economic contractions and energy shocksenergy shockA sudden disruption or price change in energy markets that affects inflation, demand, and operating costs.View full glossary entry. The strong US dollar regime also acts as an organic margin expander, as the company realizes high-margin US revenues against a partially Euro-denominated cost base.
Advisor Disagreement
What do our AI Advisors disagree about most? The primary disagreements across the reports center on the valuation multiplevaluation multipleA ratio comparing market or enterprise value with a financial measure such as earnings, revenue, book value, or cash flow.View full glossary entry and near-term margin trajectories. Some perspectives argue that the current multiple of 29x P/E is fully justified by explosive top-line growth, while others caution that it leaves zero margin of safetymargin of safetyThe difference between an estimated intrinsic value and the purchase price, intended to allow for uncertainty or analytical error.View full glossary entry, predicting a prolonged sideways valuation compression. Disagreements also stem from differing assumptions regarding the impact of recent acquisitions; some view the R&D spend as a prudent, self-funded capital allocationcapital allocationThe decision process for directing capital among operations, investment, acquisitions, debt repayment, dividends, and share repurchases.View full glossary entry strategy to bridge a clinical catalyst desert, while others penalize it as structural margin decay.
Base-Case Forces
Event Risk ScoreVery Low10/100Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Bimzelx Global Commercial Scaling | Innovation And Product | +35% | +40% | The rapid global commercialization of the flagship immunology drug Bimzelx serves as the primary growth engine. Its clinically superior dual IL-17A/F inhibition mechanism drives rapid market share capture in psoriasis and hidradenitis suppurativa, beating entrenched competitors. This highly inelastic, high-margin revenue stream is scaling across fifty countries, providing immense operating leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry and structurally elevating the company's long-term earnings power independently of broader macroeconomic cycles. |
| Fortress Balance Sheetfortress balance sheetA financial position with high liquidity and low debt, providing resilience against market volatility.View full glossary entry and Cash Flow | Capital Allocation | +18% | +15% | Operating with an exceptionally low debt-to-equity ratio of 0.21 and generating robust free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry, the company possesses absolute financial sovereignty. This unlevered capital structurecapital structureThe mix of debt and equity used to finance a business.View full glossary entry completely insulates the firm from restrictive monetary policies and refinancing risks. The massive cash generation allows the company to self-fund its extensive R&D pipeline and strategic acquisitions without relying on expensive external credit markets. |
| Rare Disease Franchise Maturation | Competitive Positioning | +15% | +18% | The successful commercialization of specialized rare disease assets like Rystiggo and Zilbrysq establishes a highly durable, secondary revenue pillar. Targeting severe unmet medical needs with small patient populations grants the company significant pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry and extended regulatory exclusivity. This franchise diversifies the cash flow base away from pure immunology, securing high-margin recurring revenues that are insulated from economic downturns. |
| BIOSECURE Supply Chainsupply chainThe network of suppliers, producers, logistics providers, distributors, and customers involved in creating and delivering a product or service.View full glossary entry Moat | Political And Geopolitical | +10% | +8.0% | As geopolitical tensions prompt US decoupling from Chinese contract manufacturers under the BIOSECURE Actbiosecure actBiosecure Act refers to legislation aimed at limiting reliance on certain biotechnology suppliers or data-linked firms for national security reasons.View full glossary entry, the company's localized European and US manufacturing footprint becomes a major strategic asset. This supply chainsupply chainThe network of suppliers, producers, logistics providers, distributors, and customers involved in creating and delivering a product or service.View full glossary entry sovereignty protects the firm from trade disruptions and regulatory penalties, allowing it to capture market share from competitors facing forced, expensive reorganizations. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| US Regulatory Pricing Pressure | Regulatory | -12% | -15% | The implementation of aggressive US pharmaceutical pricing regulations, such as executive pricing mandates and Medicare negotiation frameworks, acts as a structural drag on net realized prices. While volume growth remains robust, these policy interventions limit the terminal pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry of blockbuster biologics in the highest-margin global market, compressing peak lifecycle earnings assumptions. |
| Legacy Portfolio Patent Cliffs | Competitive Positioning | -10% | -12% | The ongoing genericization of legacy neurology and immunology assets, such as Vimpat and Cimzia, introduces a persistent revenue drag. As patent protections expire, these high-margin cash flows face rapid erosion from generics and biosimilarsbiosimilarsBiologic medicines shown to be highly similar to an approved reference product with no clinically meaningful differences.View full glossary entry. This forces the newer product cycle to grow at an accelerated pace simply to offset the baseline decay of legacy assets. |
| M&A-Driven R&D and SG&A Bloat | Capital Allocation | -8.0% | -10% | Recent clinical-stage acquisitions and the intense commercial spend required to defend market share against deeply capitalized incumbents inflate operating expenses. This elevated investment intensity temporarily compresses EBITDA marginsebitda marginsKey profitability metric measuring operational efficiency before interest, taxes, depreciation, and amortization.View full glossary entry and drags on near-term return on invested capitalreturn on invested capitalReturn on invested capital (ROIC) measures how efficiently a business generates after-tax operating profit from the capital invested in its operations.View full glossary entry, creating an optical deterioration in profitability that near-term models and algorithmic traders may penalize. |
| StagflationarystagflationAn economic condition characterized by stagnant growth, high unemployment, and high inflation.View full glossary entry Input Cost Inflation | Macroeconomic And Macrofinancial | -5.0% | -6.0% | European stagflationeuropean stagflationAn economic environment in Europe combining weak growth with persistent inflation.View full glossary entry and global logistics disruptions, including maritime chokepoint blockades, exert upward pressure on manufacturing and distribution costs. Complex biologics require specialized cold-chain logistics and packaging materials, making the supply chainsupply chainThe network of suppliers, producers, logistics providers, distributors, and customers involved in creating and delivering a product or service.View full glossary entry vulnerable to energy and chemical price spikes, which temporarily degrade gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry until localized productionlocalized productionProduction located within or near end markets to shorten supply chains or meet local requirements.View full glossary entry is fully scaled. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Exposure category | Why plausible / what changes |
|---|---|---|---|---|
| Post-Marketing Safety Signal Emergence | 15% | -35% | Innovation And Product | Real-world commercial data could reveal an unexpected, severe post-marketing safety signal associated with a core growth driver. This would lead to immediate regulatory black-box warnings or restricted prescribing protocols, collapsing the drug's commercial trajectory, destroying the primary growth thesis, and triggering a severe valuation downgrade. |
| Drastic US Price Controlsprice controlsGovernment rules that set, cap, or otherwise constrain the prices charged for specified goods or services.View full glossary entry | 25% | -25% | Regulatory | Populist political momentum in the US could result in the implementation of hard international reference pricing or sweeping price controlsprice controlsGovernment rules that set, cap, or otherwise constrain the prices charged for specified goods or services.View full glossary entry on biologics. Because the US market drives the vast majority of the company's profitability, this structural shift would permanently compress gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry and severely restrict pipeline reinvestment capacity. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Exposure category | Why plausible / what changes |
|---|---|---|---|---|
| Accelerated Broad Label Expansion | 40% | +20% | Innovation And Product | Regulatory agencies could grant earlier-than-expected approvals for the flagship immunology drug across a wider spectrum of autoimmune indications. This would dramatically expand the total addressable markettotal addressable marketTotal addressable market (TAM) is the full revenue opportunity available if a product or service achieved complete adoption within its relevant market.View full glossary entry, resetting peak sales estimates upward by billions of dollars and forcing a structural upward re-ratingupward re ratingAn increase in the valuation multiple assigned to a business or asset after market expectations improve.View full glossary entry of the equity multiple. |
| Predatory Distressed Biotech Acquisitions | 30% | +15% | Capital Allocation | Leveraging its fortress balance sheetfortress balance sheetA financial position with high liquidity and low debt, providing resilience against market volatility.View full glossary entry and massive free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry, the company could execute highly accretive, counter-cyclical acquisitions of distressed clinical-stage biotech firms. In a high-rate environment where smaller peers face capital starvation, acquiring late-stage assets at firesale valuations would rapidly replenish the long-term pipeline without diluting equity. |
Company Financial Analysis
UCB Earnings and Financials Analysis by AI
Financial figures available as of Jul 05, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
The company's financial performance is exceptionally strong, marked by a massive 25.8% jump in revenue and a doubling of its free cash flow in 2025. This explosive growth shows that the company has successfully moved past the threat of older drugs losing their patents and is now reaping huge rewards from its new immunology treatments. Analysts agree that the company is generating high-quality, real cash flows rather than relying on accounting tricks. However, there is some disagreement about the future profit outlook. Some experts warn that recent expensive company purchases and the high costs of competing in the US market will temporarily squeeze profits over the next few years. Others believe the sheer volume of new drug sales will easily overpower these costs, keeping the company on a highly profitable path. Overall, the financial trend is highly positive and supportive of long-term growth.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | EUR 7.7B | EUR 1.6B | EUR 1.9B |
| 2024 | EUR 6.2B | EUR 1.1B | EUR 920M |
| 2023 | EUR 5.3B | EUR 343M | EUR 445M |
| 2022 | EUR 5.5B | EUR 418M | EUR 748M |
| 2021 | EUR 5.8B | EUR 1.1B | EUR 1.1B |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | 17.3x | TTM | Native | EUR / EUR |
| 2024 | 26.5x | TTM | Native | EUR / EUR |
| 2023 | -- | TTM | Unavailable | EUR / EUR |
| 2022 | 33.8x | Annual | Native | EUR / EUR |
| 2021 | 18.4x | Annual | Native | EUR / EUR |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
The company enjoys outstanding profitability, with gross margins holding steady at a remarkable 71%. This means the company has immense pricing power and its products are highly profitable to make. However, there is a clear clash of opinions regarding the future direction of operating margins. Some analysts are highly optimistic, believing that as sales of its blockbuster skin drug scale up globally, profit margins will naturally expand toward the mid-20% range. Conversely, more cautious observers warn that the company faces a temporary margin squeeze. They point to the high costs of integrating recent acquisitions and the intense marketing battles required to fight off large competitors in the US. While the current stock price reflects a premium for this profitability, the general consensus is that the company's margins are highly resilient and well-protected against inflation, making it a very attractive defensive investment.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | EUR 1.2B | 15.1% | 20.1% |
| 2024 | EUR 1.3B | 21.5% | 17.3% |
| 2023 | EUR 604M | 11.5% | 6.5% |
| 2022 | EUR 400M | 7.3% | 7.6% |
| 2021 | EUR 1.1B | 19.9% | 18.3% |
Balance sheet and leverage
The company's balance sheet is described as an absolute financial fortress, offering incredible safety for investors. With an extremely low debt-to-equity ratio of 0.21 and virtually no reliance on external borrowing, the company is completely safe from rising interest rates and tight credit markets. Analysts are in complete agreement that this financial health is a massive competitive advantage. It allows the company to easily pay off its debts early and fund its multi-billion-dollar US factory expansion entirely with its own cash. There is virtually no disagreement on the safety of the balance sheet; it provides strong protection against economic downturns. Furthermore, this financial firepower gives the company the unique ability to buy up struggling, cash-starved competitors at bargain prices, turning a tough economic environment into a major growth opportunity.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | EUR 2.2B | EUR 2.5B | EUR 6M net cash | 1.38x |
| 2024 | EUR 3B | EUR 1.8B | EUR 1.5B net debt | 1.36x |
| 2023 | EUR 3B | EUR 969M | EUR 2.2B net debt | 1.32x |
| 2022 | EUR 2.9B | EUR 1.1B | EUR 2B net debt | 1.06x |
| 2021 | EUR 2.1B | EUR 1.4B | EUR 860M net debt | 1.31x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
The company is managing its spending very wisely. While traditional physical spending on factories and equipment is low at just 3.6% of revenue, the company is investing heavily in research and development (R&D) and strategic acquisitions to secure its future. A major point of consensus is the company's massive five-billion-dollar plan to build manufacturing facilities in the United States. This heavy spending is both an offensive move to support its growing drug sales and a defensive shield to protect its supply chain from global political tensions. While some analysts worry that this heavy capital spending will temporarily reduce the amount of free cash flow available, most agree it is a highly smart, self-funded investment that builds a strong competitive advantage. Opinions differ slightly on how quickly these investments will pay off, but the general agreement is that the company's low-debt model makes this heavy spending safe and highly beneficial.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | EUR 281M | EUR 1.8B |
| 2024 | EUR 322M | EUR 1.8B |
| 2023 | EUR 316M | EUR 1.6B |
| 2022 | EUR 371M | EUR 1.7B |
| 2021 | EUR 493M | EUR 1.6B |
Quarterly Forecast Scenarios
UCB Quarterly Forecast Scenarios
One row per forecast quarter. Asset scenario targets are shown in EUR; benchmark values are shown in USD.
Scroll to view all columns
| Timeline | Bear Case Stock Price (EUR) | Base Case Stock Price (EUR) | Bull Case Stock Price (EUR) | S&P 500 benchmark (USD) | Currency conversion forecast (EUR/USD) |
|---|---|---|---|---|---|
| €251.72 | €267.72 | €275.07 | $736.09 | 1.1229 | |
| €246.68 | €274.28 | €288.82 | $724.14 | 1.1119 | |
| €249.15 | €282.08 | €300.38 | $713.57 | 1.1011 | |
| €239.18 | €288.15 | €321.40 | $723.38 | 1.1013 | |
| €243.97 | €292.74 | €315.52 | $716.61 | 1.1013 | |
| €246.40 | €301.17 | €331.29 | $738.34 | 1.1016 | |
| €253.80 | €310.11 | €346.99 | $746.91 | 1.1058 | |
| €258.87 | €319.04 | €360.87 | $771.93 | 1.1079 | |
| €253.70 | €325.96 | €371.70 | $782.73 | 1.1121 | |
| €263.84 | €336.83 | €390.28 | $807.31 | 1.1138 | |
| €271.76 | €345.90 | €387.08 | $822.72 | 1.1162 | |
| €269.04 | €349.97 | €405.42 | $846.10 | 1.1220 | |
| €274.42 | €360.06 | €422.69 | $852.53 | 1.1263 | |
| €282.65 | €372.55 | €439.60 | $882.91 | 1.1278 | |
| €277.00 | €379.11 | €447.32 | $900.46 | 1.1296 | |
| €282.54 | €380.57 | €456.96 | $922.67 | 1.1291 | |
| €291.02 | €392.26 | €475.24 | $935.91 | 1.1320 | |
| €293.93 | €404.03 | €489.50 | $952.30 | 1.1343 | |
| €299.81 | €413.66 | €489.50 | $976.28 | 1.1349 | |
| €308.80 | €424.80 | €504.19 | $1,002 | 1.1376 |
Research Provenance
References & Context
This UCB consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
Independent AI Advisor panel
- AI Advisors
- 12
- AI Researchers
- 7
- AI Thinkers
- 5
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
- File size
- 90.8K bytes
- Words
- 12.8K words
- Characters
- 90.8K characters
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market Context through 2026-05-31
Download Archived SnapshotCoverage 2026-01-01 to 2026-05-31 · Knowledge cutoff 2026-05-31
- File size
- 78K bytes
- Words
- 10.9K words
- Characters
- 78K characters
This year-to-date package described the geopolitical, macroeconomic, monetary-policy, technology, trade, energy, and cross-asset developments available through the batch knowledge cutoff of 2026-05-31.
It supplied dated market and policy context, including rates, sovereign yields, equities, foreign exchange, energy, metals, and digital assets, for the forecast generation workflow.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| The Iran and Strait of Hormuz conflict shocked energy markets | 2026-02-28 | STARTED AND ONGOING |
| U.S. monetary policy entered the Warsh transition | 2026-01-30 | STARTED AND ACTIVE POLICY TRANSITION |
| Agentic AI and infrastructure spending kept expanding | 2026-01-01 | OPEN ENDED |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
34 fieldscostOfRevenue · currency_symbol · date · depreciationAndAmortization · +30 more fields
Balance sheet
64 fieldsaccountsPayable · accumulatedAmortization · accumulatedDepreciation · accumulatedOtherComprehensiveIncome · +60 more fields
Cash flow
32 fieldsbeginPeriodCashFlow · capitalExpenditures · cashAndCashEquivalentsChanges · cashFlowsOtherOperating · +28 more fields
annual: 2023-12-31–2025-12-31, 3 periods; quarterly: 2024-06-30–2025-12-31, 3 periods
Currencies cited: EUR, USD (quote EUR; primary reporting EUR; converted/valuation USD).